atp glo bioluminometric cell viability assay kit  (Biotium)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Biotium atp glo bioluminometric cell viability assay kit
    Therapeutic intervention of NTRK1 fusion-driven cell growth A. Therapeutic intervention of NTRK1 fusion-positive colon cancer cells. Therapeutic intervention of NTRK1 fusion-driven cell growth was evaluated in KM12 cells with Lestaurtinib, Crizotinib, and ARRY-470. KM12 was treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by <t>ATP-Glo</t> <t>Bioluminometric</t> Cell Viability Assay kit (Biotium Inc.). KM12 was sensitive to Lestaurtinib and ARRY-470 with 10.7 nM and 3.2 nM of CC50, respectively. Crizotinib was less potent to inhibit KM12 proliferation with CC50 = 184.8 nM. B. Therapeutic intervention of NTRK1 fusion-negative colon cancer cells. HCT116 was resistant to ARRY-470. Crizotinib was more potent to inhibit HCT116 proliferation with CC50 = 568 nM.
    Atp Glo Bioluminometric Cell Viability Assay Kit, supplied by Biotium, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atp glo bioluminometric cell viability assay kit/product/Biotium
    Average 90 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    atp glo bioluminometric cell viability assay kit - by Bioz Stars, 2020-04
    90/100 stars

    Related Products / Commonly Used Together

    km12
    hct116 kclb
    atp levels

    Images

    1) Product Images from "NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer"

    Article Title: NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer

    Journal: Oncotarget

    doi: 10.18632/oncotarget.6724

    Therapeutic intervention of NTRK1 fusion-driven cell growth A. Therapeutic intervention of NTRK1 fusion-positive colon cancer cells. Therapeutic intervention of NTRK1 fusion-driven cell growth was evaluated in KM12 cells with Lestaurtinib, Crizotinib, and ARRY-470. KM12 was treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by ATP-Glo Bioluminometric Cell Viability Assay kit (Biotium Inc.). KM12 was sensitive to Lestaurtinib and ARRY-470 with 10.7 nM and 3.2 nM of CC50, respectively. Crizotinib was less potent to inhibit KM12 proliferation with CC50 = 184.8 nM. B. Therapeutic intervention of NTRK1 fusion-negative colon cancer cells. HCT116 was resistant to ARRY-470. Crizotinib was more potent to inhibit HCT116 proliferation with CC50 = 568 nM.
    Figure Legend Snippet: Therapeutic intervention of NTRK1 fusion-driven cell growth A. Therapeutic intervention of NTRK1 fusion-positive colon cancer cells. Therapeutic intervention of NTRK1 fusion-driven cell growth was evaluated in KM12 cells with Lestaurtinib, Crizotinib, and ARRY-470. KM12 was treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by ATP-Glo Bioluminometric Cell Viability Assay kit (Biotium Inc.). KM12 was sensitive to Lestaurtinib and ARRY-470 with 10.7 nM and 3.2 nM of CC50, respectively. Crizotinib was less potent to inhibit KM12 proliferation with CC50 = 184.8 nM. B. Therapeutic intervention of NTRK1 fusion-negative colon cancer cells. HCT116 was resistant to ARRY-470. Crizotinib was more potent to inhibit HCT116 proliferation with CC50 = 568 nM.

    Techniques Used: Viability Assay

    Related Articles

    Generated:

    Article Title: The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1−/− mice
    Article Snippet: ATP levels were determined using a commercially available ATP-Glo ™ Bioluminometric Cell Viability Assay kit (#30020-1, Biotium Inc., Hayward, CA, USA). .. ATP calibration curves were generated according to kit.

    Luciferase:

    Article Title: The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1−/− mice
    Article Snippet: ATP levels were determined using a commercially available ATP-Glo ™ Bioluminometric Cell Viability Assay kit (#30020-1, Biotium Inc., Hayward, CA, USA). .. The assay uses firefly luciferase in the presence of ATP, which oxidizes D-luciferin resulting in the emission of light.

    Viability Assay:

    Article Title: NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer
    Article Snippet: .. KM12 and HCT116 (KCLB) were treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by the ATP-Glo Bioluminometric Cell Viability Assay Kit (Biotium Inc., USA). ..

    Article Title: The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1−/− mice
    Article Snippet: .. ATP levels were determined using a commercially available ATP-Glo ™ Bioluminometric Cell Viability Assay kit (#30020-1, Biotium Inc., Hayward, CA, USA). .. ATP calibration curves were generated according to kit.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    Biotium atp glo bioluminometric cell viability assay kit
    Therapeutic intervention of NTRK1 fusion-driven cell growth A. Therapeutic intervention of NTRK1 fusion-positive colon cancer cells. Therapeutic intervention of NTRK1 fusion-driven cell growth was evaluated in KM12 cells with Lestaurtinib, Crizotinib, and ARRY-470. KM12 was treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by <t>ATP-Glo</t> <t>Bioluminometric</t> Cell Viability Assay kit (Biotium Inc.). KM12 was sensitive to Lestaurtinib and ARRY-470 with 10.7 nM and 3.2 nM of CC50, respectively. Crizotinib was less potent to inhibit KM12 proliferation with CC50 = 184.8 nM. B. Therapeutic intervention of NTRK1 fusion-negative colon cancer cells. HCT116 was resistant to ARRY-470. Crizotinib was more potent to inhibit HCT116 proliferation with CC50 = 568 nM.
    Atp Glo Bioluminometric Cell Viability Assay Kit, supplied by Biotium, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atp glo bioluminometric cell viability assay kit/product/Biotium
    Average 90 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    atp glo bioluminometric cell viability assay kit - by Bioz Stars, 2020-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    Therapeutic intervention of NTRK1 fusion-driven cell growth A. Therapeutic intervention of NTRK1 fusion-positive colon cancer cells. Therapeutic intervention of NTRK1 fusion-driven cell growth was evaluated in KM12 cells with Lestaurtinib, Crizotinib, and ARRY-470. KM12 was treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by ATP-Glo Bioluminometric Cell Viability Assay kit (Biotium Inc.). KM12 was sensitive to Lestaurtinib and ARRY-470 with 10.7 nM and 3.2 nM of CC50, respectively. Crizotinib was less potent to inhibit KM12 proliferation with CC50 = 184.8 nM. B. Therapeutic intervention of NTRK1 fusion-negative colon cancer cells. HCT116 was resistant to ARRY-470. Crizotinib was more potent to inhibit HCT116 proliferation with CC50 = 568 nM.

    Journal: Oncotarget

    Article Title: NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer

    doi: 10.18632/oncotarget.6724

    Figure Lengend Snippet: Therapeutic intervention of NTRK1 fusion-driven cell growth A. Therapeutic intervention of NTRK1 fusion-positive colon cancer cells. Therapeutic intervention of NTRK1 fusion-driven cell growth was evaluated in KM12 cells with Lestaurtinib, Crizotinib, and ARRY-470. KM12 was treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by ATP-Glo Bioluminometric Cell Viability Assay kit (Biotium Inc.). KM12 was sensitive to Lestaurtinib and ARRY-470 with 10.7 nM and 3.2 nM of CC50, respectively. Crizotinib was less potent to inhibit KM12 proliferation with CC50 = 184.8 nM. B. Therapeutic intervention of NTRK1 fusion-negative colon cancer cells. HCT116 was resistant to ARRY-470. Crizotinib was more potent to inhibit HCT116 proliferation with CC50 = 568 nM.

    Article Snippet: KM12 and HCT116 (KCLB) were treated at 0.64 nM to 10 μM of each compounds for 4 days, and cell growth was evaluated by the ATP-Glo Bioluminometric Cell Viability Assay Kit (Biotium Inc., USA).

    Techniques: Viability Assay